SCHEMBL24745217

SCHEMBL24745217

CCOC(=O)c1[nH]c2c(Br)c(Cl)ccc2c1CCCOc1cc(OC)cc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 15/20 0.43
BCL2 P10415 3/20 0.42
BCL2L1 Q07817 1/20 0.42
CDC25B P30305 1/20 0.42
HTR6 P50406 2/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1F P30939 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39
IRAK1 P51617 2/20 0.39
NEK4 P51957 2/20 0.39
PRKCD Q05655 2/20 0.39
MAP4K2 Q12851 2/20 0.39
CAMK2B Q13554 2/20 0.39
CAMK2G Q13555 2/20 0.39
CAMK2D Q13557 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000670 1.00 MCL1 (0.43) MCL1BCL2BCL2L1CDC25BHTR6
SCHEMBL30079953 0.88 MCL1 (0.39) MCL1BCL2BCL2L1
SCHEMBL28524865 0.88 MCL1 (0.39) MCL1BCL2BCL2L1
SCHEMBL30000950 0.88 MCL1 (0.55) MCL1BCL2BCL2L1IRAK1NEK4
SCHEMBL22436876 0.88 MCL1 (0.55) MCL1BCL2BCL2L1IRAK1NEK4
SCHEMBL22436674 0.85 MCL1 (0.46) MCL1BCL2BCL2L1IRAK1NEK4
SCHEMBL29470900 0.85 MCL1 (0.46) MCL1BCL2BCL2L1IRAK1NEK4
SCHEMBL30000206 0.83 MCL1 (0.54) MCL1BCL2BCL2L1NEK4PRKCD
SCHEMBL24745215 0.83 MCL1 (0.54) MCL1BCL2BCL2L1NEK4PRKCD
SCHEMBL24774225 0.80 MCL1 (0.42) MCL1BCL2BCL2L1IRAK1NEK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022255888-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed